دورية أكاديمية
أعرض في EDS

Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.

التفاصيل البيبلوغرافية
العنوان: Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
المؤلفون: Jokar MH; Rheumatology Diseases Research Center, Mashhad University of Medical Sciences, Iran., Baghbani B; North Khorasan University of Medical Sciences, Bojnord, Iran., Geraylow KR; Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran., Shariati J; Rheumatology Diseases Research Center, Mashhad University of Medical Sciences, Iran., Mehrad-Majd H; Department of Clinical Research Development, Ghaem Hospital, Mashhad University of Medical Sciences, Iran., Mirfeizi Z; Rheumatology Diseases Research Center, Mashhad University of Medical Sciences, Iran., Hashemzadeh K; Rheumatology Diseases Research Center, Mashhad University of Medical Sciences, Iran.
المصدر: Reumatologia [Reumatologia] 2022; Vol. 60 (6), pp. 392-398. Date of Electronic Publication: 2022 Dec 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Termedia Country of Publication: Poland NLM ID: 20130190R Publication Model: Print-Electronic Cited Medium: Print ISSN: 0034-6233 (Print) Linking ISSN: 00346233 NLM ISO Abbreviation: Reumatologia Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2005- : Poznań : Termedia
Original Publication: 1963-1992 : Warszawa : Panstwowy Zakład Wydawnictw Lekarskich
مستخلص: Introduction: Systemic sclerosis (SSc) is an autoimmune, connective tissue disorder of unknown etiology which causes vasculopathy and fibrosis. Raynaud's phenomenon (RP) is a common complication of SSc, which leads to ischemia and gangrenes. Treatment of RP is a clinical problem and often remains insufficient.This study aimed to evaluate the therapeutic efficacy of local injections of botulinum toxin type A (BTX-A) in improving the symptoms of Raynaud's phenomenon (RP) secondary to scleroderma.
Material and Methods: This parallel single-blinded, placebo-controlled clinical trial enrolled 29 patients with scleroderma. Participants received BTX-A in the first, 2 nd , 3 rd , and 4 th dorsal web spaces and the base of the thumb and small finger of the non-dominant hand and 2.5 ml of sterile normal saline in the opposite hand. Pre-injection measurements and post-injection follow-up evaluations at months 1 and 4 were performed. We compared the outcomes using the paired Student's t -test.
Results: The change in pain severity between pre-injection and month 1 follow-up was significantly larger in the BTX-A group ( p -value = 0.04). Between pre-injection and month 1 and month 4, the changes in the Raynaud's condition score (RCS) ( p -value = 0.02, 0.004, respectively) and the number of Raynaud's attacks ( p -value = 0.006, 0.001, respectively) were significantly greater in the BTX-A group. No significant difference was found in terms of paresthesia, skin thickening, upper extremity function, ulcer diameter, number of ulcers, or Raynaud's attack duration between the two groups ( p -value > 0.05). In time, the decrease in pain severity, paresthesia, RCS, number of ulcers, and ulcer diameter, and the increase in upper extremity function were significantly greater in the BTX-A group as compared to the placebo group ( p < 0.05).
Conclusions: Our study showed that local injection of BTX-A is safe and has beneficial therapeutic effects on RP and RP-related digital ulcers in SSc patients.
Competing Interests: The authors declare no conflict of interest.
(Copyright: © 2022 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie.)
References: Dermatol Ther. 2020 Nov;33(6):e14182. (PMID: 32794364)
Reumatol Clin (Engl Ed). 2021 Jun-Jul;17(6):357-363. (PMID: 32591260)
Ann Plast Surg. 2015 Dec;75(6):637-43. (PMID: 26418780)
Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101684. (PMID: 33965340)
Arch Med Sci. 2016 Aug 1;12(4):864-70. (PMID: 27478469)
J Hand Surg Am. 2009 Mar;34(3):446-52. (PMID: 19258141)
Arthritis Rheum. 2013 Nov;65(11):2737-47. (PMID: 24122180)
J Hand Surg Am. 2010 Dec;35(12):2085-92. (PMID: 21134617)
Am J Physiol Heart Circ Physiol. 2001 Nov;281(5):H2124-32. (PMID: 11668074)
Ann Chir Plast Esthet. 2013 Dec;58(6):658-62. (PMID: 22204894)
J Scleroderma Relat Disord. 2020 Jun 1;5(2):130-136. (PMID: 34095502)
J Hand Surg Eur Vol. 2014 Oct;39(8):876-80. (PMID: 24369360)
J Dermatol. 2016 Jan;43(1):56-62. (PMID: 26173902)
Ann Plast Surg. 2016 Sep;77(3):318-23. (PMID: 26808752)
Eur J Clin Invest. 2004 Apr;34(4):312-3. (PMID: 15086364)
Plast Reconstr Surg. 2007 Jan;119(1):217-226. (PMID: 17255677)
Nat Rev Rheumatol. 2010 Aug;6(8):453-60. (PMID: 20585340)
J Clin Invest. 2007 Mar;117(3):557-67. (PMID: 17332883)
J Bone Joint Surg Am. 2005 May;87(5):1038-46. (PMID: 15866967)
J Rheumatol. 1995 Jul;22(7):1281-5. (PMID: 7562759)
Plast Reconstr Surg. 2009 Jul;124(1):191-201. (PMID: 19568080)
Rheum Dis Clin North Am. 2015 Aug;41(3):419-38. (PMID: 26210127)
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. (PMID: 22588748)
Arthritis Rheumatol. 2017 Aug;69(8):1661-1669. (PMID: 28426903)
Eur J Rheumatol. 2018 Dec;5(4):224-229. (PMID: 30501848)
Rheumatol Int. 2021 May;41(5):943-949. (PMID: 32447423)
Arthritis Rheum. 2010 Sep;62(9):2569-81. (PMID: 20872595)
فهرسة مساهمة: Keywords: Raynaud’s phenomenon; botulinum toxin type A; systemic sclerosis
تواريخ الأحداث: Date Created: 20230123 Latest Revision: 20230124
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9847105
DOI: 10.5114/reum.2022.120757
PMID: 36683833
قاعدة البيانات: MEDLINE
الوصف
تدمد:0034-6233
DOI:10.5114/reum.2022.120757